Literature DB >> 3108189

Cause and prevention of mafosfamide-induced venous pain.

P Hilgard, J Pohl.   

Abstract

An experimental rat model for the study of venous pain induced by 4-hydroxy-cyclophosphamide (4-OH-CP) derivatives was developed and validated. Using various metabolites and chemical variants of 4-OH-CP it was found that pain induction was independent from the compound's alkylating activity but possibly related to the spontaneous generation of minute amounts of acrolein from the 4-OH-CP molecule. Accordingly, the pain could be prevented by the addition of thiol compounds such as mesna or N-acetyl-cysteine.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3108189     DOI: 10.1007/bf00173510

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  4 in total

1.  Chemical characterization of ASTA Z 7557 (INN mafosfamide, CIS-4-sulfoethylthio-cyclophosphamide), a stable derivative of 4-hydroxy-cyclophosphamide.

Authors:  U Niemeyer; J Engel; G Scheffler; K Molge; D Sauerbier; W Weigert
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

2.  Phase-I study of mafosfamide-cyclohexylamine (ASTA-Z-7557, NSC 345 842) and limited phase-I data on mafosfamide-lysine.

Authors:  U Bruntsch; G Groos; T A Hiller; H Wandt; F J Tigges; W M Gallmeier
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

3.  Pharmacokinetics and mechanism of action of detoxifying low-molecular-weight thiols.

Authors:  N Brock; P Hilgard; J Pohl; K Ormstad; S Orrenius
Journal:  J Cancer Res Clin Oncol       Date:  1984       Impact factor: 4.553

4.  alpha-/beta-Triglycidyl-urazol (TGU, NSC 332488, I.N.N.: ANAXIRONE): a new chemotherapeutic agent.

Authors:  P Hilgard; M Peukert; J Pohl
Journal:  Cancer Treat Rev       Date:  1984-06       Impact factor: 12.111

  4 in total
  1 in total

1.  D-19575--a sugar-linked isophosphoramide mustard derivative exploiting transmembrane glucose transport.

Authors:  J Pohl; B Bertram; P Hilgard; M R Nowrousian; J Stüben; M Wiessler
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.